Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4347-4357

  Gilabert Oriol, Roger ^a   Thakur, Mayank ^a   Von Mallinckrodt, Benedicta ^a   Hug, Thomas ^a   Wiesner, Burkhard ^b   Eichhorst, Jenny ^b   Melzig, Matthias F ^c   Fuchs, Hendrik ^a   Weng, Alexander ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Leibnitz Institut fuer molekulare Pharmakologie FMP   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

cell mediated cytotoxicity; Erbitux; Herceptin; immunotoxin; saporin; triterpenoid saponin

Indexed keywords

CETUXIMAB; IMMUNOTOXIN; SAPORIN; TRASTUZUMAB; TRITERPENOID;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DISULFIDE BOND; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMMUNOTOXINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SAPONINS; TRITERPENES;

EID: 84887329795     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400444q     Document Type: Article

References (31)

1. Dimitrov, D. S.; Marks, J. D. Therapeutic antibodies: current state and future trends-is a paradigm change coming soon? Methods Mol. Biol. 2009, 525, 1-27 xiii
2. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future Br. J. Pharmacol. 2009, 157 (2) 220-33
3. Scott, A. M.; Allison, J. P.; Wolchok, J. D. Monoclonal antibodies in cancer therapy Cancer Immun. 2012, 12, 14
4. Abes, R.; Teillaud, J. L. Modulation of tumor immunity by therapeutic monoclonal antibodies Cancer Metastasis Rev. 2011, 30 (1) 111-24
5. Thiery, J.; Keefe, D.; Boulant, S.; Boucrot, E.; Walch, M.; Martinvalet, D.; Goping, I. S.; Bleackley, R. C.; Kirchhausen, T.; Lieberman, J. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells Nat. Immunol. 2011, 12 (8) 770-7
6. Nahta, R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer ISRN Oncol. 2012, 2012, 428062
7. Vlacich, G.; Coffey, R. J. Resistance to EGFR-targeted therapy: a family affair Cancer Cell 2011, 20 (4) 423-5
8. Wong, A. L.; Lee, S. C. Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer Int. J. Breast Cancer 2012, 2012, 415170
9. Kreitman, R. J. Immunotoxins for targeted cancer therapy AAPS J. 2006, 8 (3) E532-51
10. Dillman, R. O. Cancer immunotherapy Cancer Biother. Radiopharm. 2011, 26 (1) 1-64
11. Frankel, A. E. Reducing the immune response to immunotoxin Clin. Cancer Res. 2004, 10 (1 Pt 1) 13-5
12. Hebestreit, P.; Weng, A.; Bachran, C.; Fuchs, H.; Melzig, M. F. Enhancement of cytotoxicity of lectins by Saponinum album Toxicon 2006, 47 (3) 330-5
13. Weng, A.; Thakur, M.; Beceren-Braun, F.; Bachran, D.; Bachran, C.; Riese, S. B.; Jenett-Siems, K.; Gilabert-Oriol, R.; Melzig, M. F.; Fuchs, H. The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins Mol. Oncol. 2012, 6 (3) 323-32
14. Thakur, M.; Mergel, K.; Weng, A.; Frech, S.; Gilabert-Oriol, R.; Bachran, D.; Melzig, M. F.; Fuchs, H. Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement Biosens. Bioelectron. 2012, 35 (1) 503-6
15. Weng, A.; Thakur, M.; von Mallinckrodt, B.; Beceren-Braun, F.; Gilabert-Oriol, R.; Wiesner, B.; Eichhorst, J.; Bottger, S.; Melzig, M. F.; Fuchs, H. Saponins modulate the intracellular trafficking of protein toxins J. Controlled Release 2012, 164 (1) 74-86
16. Thakur, M.; Mergel, K.; Weng, A.; von Mallinckrodt, B.; Gilabert-Oriol, R.; Durkop, H.; Melzig, M. F.; Fuchs, H. Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: An evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice Mol. Oncol. 2013, 7 (3) 475-83
17. Heisler, I.; Keller, J.; Tauber, R.; Sutherland, M.; Fuchs, H. A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins Int. J. Cancer 2003, 103 (2) 277-82
18. Seidel, U. J.; Schlegel, P.; Lang, P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Front. Immunol. 2013, 4, 76
19. Pastan, I.; Hassan, R.; FitzGerald, D. J.; Kreitman, R. J. Immunotoxin treatment of cancer Annu Rev Med 2007, 58, 221-37
20. Fuchs, H.; Bachran, C. Targeted tumor therapies at a glance Curr. Drug Targets 2009, 10 (2) 89-93
21. Barnea, I.; Ben-Yosef, R.; Karaush, V.; Benhar, I.; Vexler, A. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies Head Neck 2013, 35 (8) 1171-7
22. Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies Oncogene 2013, 10.1038/onc.2012.612
23. Yip, W. L.; Weyergang, A.; Berg, K.; Tonnesen, H. H.; Selbo, P. K. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells Mol. Pharmaceutics 2007, 4 (2) 241-51
24. Berstad, M. B.; Weyergang, A.; Berg, K. Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence Biochim. Biophys. Acta 2012, 1820 (12) 1849-58
25. Heisler, I.; Sutherland, M.; Bachran, C.; Hebestreit, P.; Schnitger, A.; Melzig, M. F.; Fuchs, H. Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells J. Controlled Release 2005, 106 (1-2) 123-37
26. Bachran, C.; Durkop, H.; Sutherland, M.; Bachran, D.; Muller, C.; Weng, A.; Melzig, M. F.; Fuchs, H. Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way J. Immunother. 2009, 32 (7) 713-25
27. Jefferis, R.; Lund, J. Interaction sites on human IgG-Fc for FcgammaR: current models Immunol. Lett. 2002, 82 (1-2) 57-65
28. Patel, D.; Lahiji, A.; Patel, S.; Franklin, M.; Jimenez, X.; Hicklin, D. J.; Kang, X. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface Anticancer Res. 2007, 27 (5A) 3355-66
29. Vu, T.; Claret, F. X. Trastuzumab: updated mechanisms of action and resistance in breast cancer Front. Oncol. 2012, 2, 62
30. Saito, G.; Swanson, J. A.; Lee, K. D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv. Drug Delivery Rev. 2003, 55 (2) 199-215
31. Stirpe, F.; Bailey, S.; Miller, S. P.; Bodley, J. W. Modification of ribosomal RNA by ribosome-inactivating proteins from plants Nucleic Acids Res. 1988, 16 (4) 1349-57